Jon Miller's questions to Zymeworks Inc (ZYME) leadership • Q3 2024
Question
Jon Miller asked if the share repurchase program achieved its goals, about the potential for future business development deals, and how the company's ADC technology addresses tumors with variable antigen expression.
Answer
CEO Kenneth Galbraith affirmed the share repo's success and noted the company still feels undervalued. He stated that while the pipeline is wholly-owned, they expect to form partnerships to accelerate development. CSO Dr. Paul Moore explained their ADC design uses a multi-pronged approach, combining on-target effects, bystander activity, and a controlled payload release to effectively treat tumors with heterogeneous expression.